Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Arena Pharmaceuticals

SAN DIEGO, May 27, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by...

Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, May 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and...

Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

SAN DIEGO, May 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,175 shares of its common stock to 13 new employees...

Arena Pharmaceuticals - Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena (ARNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Arena (ARNA) Stock a Solid Choice Right Now?

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2020 Results - Earnings Call Transcript

Corbus Pharmaceuticals Holdings

Trulieve Cannabis Corp.

Not all pot stocks are wildly volatile, and there are safer options out there for cannabis investors.

3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational Pot

Arena Pharmaceuticals: Buy The Dip Ahead Of Catalyst-Rich 2020 And 2021

Arena (ARNA) has sufficient funds to support its pipeline progress. However, competitive targeted indications and plunging revenues raise concerns.

Arena's Pipeline Holds Promise, Plunging Revenues a Concern

Aurora Cannabis

Amyris

OrganiGram Holdings Inc.

Tilray Brands

Psychedelic Medicine Stocks Capture The Attention Of Investors

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the fourth quarter of 2019 while revenues beat estimates.

Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q4 2019 Results - Earnings Call Transcript

A study finds an increased risk of cancer, and the manufacturer complies with the FDA's request.

FDA Asks That Weight Loss Drug Belviq Be Pulled From the Market

Cara Therapeutics

Cronos Group

Greenlane Holdings

GW Pharmaceuticals

Marrone Bio Innovations

New Age Beverages

Intec Parent

Psychemedics

SNDL Inc.

Therapix Biosciences

Village Farms International

Zynerba Pharmaceuticals

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

Honeywell

IQVIA Hlds

Micron Technology

Tradeweb Markets

Vistra Energy

Every time a new year rolls around, it creates a timely excuse for Wall Street brokerage firms and research firms to refresh their annual views, economic outlooks and make changes to their lists of top stock picks.

6 New Credit Suisse Top Number-One Stock Picks for 2020

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

Arena Pharmaceuticals, Inc. (ARNA) Presents at Evercore HealthCONx Broker Conference Call - (Transcript)

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.

Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat

Hint: This number won't be found on the biotech's top or bottom lines.

Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big

Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2019 Results - Earnings Call Transcript

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2019 Results - Earnings Call Transcript

Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Arena Pharmaceuticals Stock (ARNA)